BCWM
CRL icon

Bartlett & Co Wealth Management’s Charles River Laboratories CRL Stock Holding History

Bartlett & Co Wealth Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.04K Buy
9
+4
+80% +$712 ﹤0.01% 1165
2026
Q1 		$862 Hold
5
– – ﹤0.01% 1143
2025
Q4 		$997 Hold
5
– – ﹤0.01% 1148
2025
Q3 		$782 Sell
5
-18
-78% -$2.86K ﹤0.01% 1128
2025
Q2 		$3.49K Buy
+23
New +$3.07K ﹤0.01% 1043
2021
Q4 		– Sell
-10
Closed -$4.13K – 497
2021
Q3 		$4.13K Buy
+10
New +$4.15K ﹤0.01% 787

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Bartlett & Co Wealth Management's CRL Position: Q2 2026 in Review

Bartlett & Co Wealth Management increased its Charles River Laboratories (CRL) stake by 80% in Q2 2026, buying an estimated $712 and bringing the position to 9 shares worth $2.04K. The position accounts for ﹤0.01% of the portfolio, ranked #1165.

Bartlett & Co Wealth Management first reported a position in CRL in Q3 2021 and has held it in 6 quarters since. The position peaked at $4.13K in Q3 2021. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Bartlett & Co Wealth Management held 9 shares of Charles River Laboratories worth $2.04K as of Q2 2026.
  • Bartlett & Co Wealth Management bought 4 Charles River Laboratories shares in Q2 2026, an estimated $712.
  • Charles River Laboratories made up ﹤0.01% of Bartlett & Co Wealth Management's portfolio in Q2 2026, its #1165 holding.
  • Bartlett & Co Wealth Management first reported a position in Charles River Laboratories in Q3 2021 and has held it in 6 quarters since.
  • Bartlett & Co Wealth Management's Charles River Laboratories position peaked at $4.13K in Q3 2021.
  • 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Bartlett & Co Wealth Management's 13F filing for Q2 2026, filed 24 Jul 2026.